Integrated Diagnostics Holdings (LSE:IDHC) reported revenue of EGP 4.9 billion for the first half of 2026, an increase of 37% from the prior-year period, as test volumes rose 20% and revenue per test increased 14%.
Gross profit increased 41%, while EBITDA rose 38% and net profit was 47% higher. The company attributed the performance to higher operating leverage, procurement efficiencies and cost management, alongside continued investment in new branches and specialised services.
Second-quarter revenue increased 42% year on year, while EBITDA rose 50%. The company said the quarterly performance reflected demand across its core markets and higher utilisation in both contract and walk-in patient segments.
IDH expanded its network to 839 branches during the period. The group opted not to pay an additional dividend, saying it had decided to retain cash because of geopolitical uncertainty and planned expansion projects.
Founding shareholder vehicle Hena Holdings increased its ownership of IDH to 56.67%, leaving 43.33% of the company’s shares in public hands.
The company ended the first half with a positive net cash position. IDH said operating cash generation and working capital management supported its liquidity while capital expenditure requirements increased.
The group is retaining balance-sheet flexibility and US dollar liquidity as it continues investment across its diagnostics and radiology operations.
More about Integrated Diagnostics Holdings
Integrated Diagnostics Holdings is a London-listed medical diagnostics provider operating across Egypt, Jordan, Nigeria, Saudi Arabia and Sudan. The group provides laboratory testing and radiology services to contract and walk-in patients through its branch network.
IDH has been expanding its branch presence, including in Egypt and Saudi Arabia, while investing in specialised services including radiology and Biolab KSA.
Leave a Reply